Search results for "CLINICAL TRIALS"

showing 10 items of 490 documents

Rabbit anti-thymocyte globulin in liver transplantation: All that glitters is not gold, but 1000 patients are so many to dazzle

2012

AdultPathologymedicine.medical_specialtyBiopsymedicine.medical_treatmentLiver transplantationEnd Stage Liver DiseaseRecurrenceBiopsyAnimalsHumansMedicineAntilymphocyte SerumClinical Trials as TopicTransplantationHepatologymedicine.diagnostic_testbusiness.industryCase-control studyEnd stage liver diseaseHepatitis CMiddle Agedmedicine.diseaseHepatitis CLiver TransplantationAnti-thymocyte globulinCase-Control StudiesImmunologySurgeryRabbitsbusinessImmunosuppressive AgentsLiver Transplantation
researchProduct

Idursulfase treatment of Hunter syndrome in children younger than 6 years: results from the Hunter Outcome Survey.

2011

Purpose: To use the Hunter Outcome Survey, an international database, to assess the safety and effectiveness of enzyme replacement therapy with idursulfase in patients with Hunter syndrome who started treatment before 6 years of age. Methods: The study population included all patients enrolled in the Hunter Outcome Survey who started idursulfase infusions (0.5 mg/kg every other week) before 6 years of age and who had at least one follow-up examination recorded. Results: The study population included 124 patients, younger than 6 years, who had a mean age at start of idursulfase of 3.6 ± 1.6 years (mean ± SD). The mean duration of treatment was 22.9 ± 14.6 months. A total of 69 infusion-relat…

AdultPediatricsmedicine.medical_specialtyAdolescentDatabases FactualIdursulfaseUrineIduronate Sulfatasechemistry.chemical_compoundYoung AdultInternational databaseMedicineHumansEnzyme Replacement TherapyYoung adultChildInfusions IntravenousGenetics (clinical)GlycosaminoglycansMucopolysaccharidosis IICreatinineClinical Trials as Topicbusiness.industryData CollectionInfantHunter syndromeEnzyme replacement therapymedicine.diseaseTreatment OutcomechemistryChild PreschoolPopulation studybusinessmedicine.drugGenetics in medicine : official journal of the American College of Medical Genetics
researchProduct

Immunologic diseases and brain tumors

2010

To do a bibliographic review of the given association of atopic [AD] and immunological diseases with central nerve system tumors [CNST] described a few years ago and to know the knowledge available. It gives an overview of the studies describing this association, and those explaining its mechanism. A negative association of AD with CNST stands out in case-control studies, which is not observed in cohort studies. The greatest association is seen for gliomas and is less significant for meningiomas. A clearer definition for the AD under study, tumour types, and the exact biochemical and clinical parameters to help diagnoses are the recommended as well as to establish an aetiologic and temporal…

AdultRiskPathologymedicine.medical_specialtyImmunologyMEDLINENegative associationBioinformaticsCohort StudiesImmunologic diseasesImmunology and AllergyMedicineAnimalsHumansChildPharmacologyClinical Trials as Topicbusiness.industryMechanism (biology)Brain NeoplasmsCase-control studyImmunityGeneral MedicineUnited StatesEuropeImmune System DiseasesCase-Control StudiesImmunological diseasesCentral nerve systembusinessCohort study
researchProduct

Does the diagnosis center influence the prognosis of ovarian cancer patients submitted to neoadjuvant chemotherapy?

2015

To compare prognosis of advanced epithelial ovarian cancer (AEOC) patients based on where the first surgical assessment was performed.Retrospective analysis of primary AEOC patients was performed and three groups were formed based on where the decision of primary treatment was taken: Internal, if the decision was carried out at our Institution (PDS (Primary Debulking Surgery), I-IDS (Internal-Interval Debulking Surgery)) and Referred in case women were referred after neoadjuvant chemotherapy (NACT) from other Centers (R-IDS (Referred-Interval Debulking Surgery)).Among 573 AEOC, 279 (48.7%) were PDS and 294 (51.3%) IDS. In particular, 134 of 294 (45.6%) were R-IDS and 160 (54.4%) were I-IDS.…

AdultTertiary Care CenterCarcinoma Ovarian EpithelialDisease-Free SurvivalcytoreductionTertiary Care CentersOvarian cancerAntineoplastic Combined Chemotherapy ProtocolsHumansNeoplasms Glandular and EpithelialAgedNeoplasm StagingAged 80 and overOvarian NeoplasmsCytoreduction; Interval debulking surgery; Ovarian cancer; PrognosisClinical Trials as TopicAntineoplastic Combined Chemotherapy ProtocolOvarian NeoplasmMiddle AgedPrognosisNeoadjuvant TherapySettore MED/40 - GINECOLOGIA E OSTETRICIAinterval debulking surgeryFemaleprognosineoadjuvant chemotherapyHuman
researchProduct

Types of Adult Attention-Deficit/Hyperactivity Disorder: A Replication Analysis.

2019

OBJECTIVE Research supports the importance of emotional symptoms in adults with attention-deficit/hyperactivity disorder (ADHD), which are not reflected in the DSM-5 or ICD-10 criteria. The Wender-Reimherr Adult Attention Deficit Disorder Scale (WRAADDS) assesses these symptoms, plus inattention, hyperactivity, and impulsivity. This scale allowed us to divide adult ADHD into 2 subtypes in a 2015 publication: ADHD inattentive presentation and ADHD emotional dysregulation presentation. The present study refines this observation using a larger, more diverse sample. METHODS Eight double-blind adult ADHD clinical trials (encompassing 1,490 subjects) were selected because they included assessment…

AdultTreatment responseImpulsivityFactor structurebehavioral disciplines and activities03 medical and health sciences0302 clinical medicineRating scalemental disordersMedicineAttention deficit hyperactivity disorderHumansAffective SymptomsClinical Trials as Topicbusiness.industryAttention deficit disordermedicine.diseaseEmotional dysregulation030227 psychiatryClinical trialPsychiatry and Mental healthAttention Deficit Disorder with Hyperactivitymedicine.symptombusinessFactor Analysis Statistical030217 neurology & neurosurgeryClinical psychologyThe Journal of clinical psychiatry
researchProduct

Family perceptions of clinical research and the informed consent process in the ICU

2020

Abstract Purpose We investigated experiences of families who provide consent for research on behalf of a loved-one hospitalized in intensive care (ICU). Methods Multicentre, qualitative, descriptive study using semi-directive interviews in 3 ICUs. Eligible relatives were aged >18 years, and had provided informed consent for a clinical trial on behalf of a patient hospitalized in ICU. Interviews were conducted from 06/2018 to 06/2019 by a qualified sociologist, recorded and transcribed. Results Fifteen relatives were interviewed; average age 50.3 ± 15 years. All emphasized their interest in clinical research, seeing it as a duty. Involving their loved-one in research allowed them to find mea…

Adultmedicine.medical_specialtyCritical Caremedia_common.quotation_subjectCritical Care and Intensive Care Medicine03 medical and health sciences0302 clinical medicineInformed consentPhysiciansIntensive careHumansMedicineFamilyDutyQualitative ResearchAgedmedia_commonClinical Trials as TopicInformed Consentbusiness.industryInformation quality030208 emergency & critical care medicineMiddle AgedClinical trialIntensive Care UnitsClinical researchCaregivers030228 respiratory systemFamily medicineDescriptive researchbusinessQualitative researchJournal of Critical Care
researchProduct

Effectiveness and safety of once-daily aminoglycosides: A meta-analysis

1996

The effectiveness and safety of once-daily versus several-times-daily aminoglycosides were studied in a meta-analysis. MEDLINE for 1988 to 1995 was searched, and additional studies were identified from review articles and references in retrieved articles. Studies selected for meta-analysis were randomized controlled clinical trials in nonneutropenic adult patients comparing the clinical effectiveness or nephrotoxicity or ototoxicity of once-daily with several-times-daily aminoglycosides. Differences between groups were expressed as odds ratios. The results were combined by the procedure of Mantel and Haenszel, and 95% confidence intervals and exact confidence intervals were computed. An odd…

Adultmedicine.medical_specialtyMEDLINEInfectionsDrug Administration ScheduleNephrotoxicityOtotoxicityInternal medicinemedicineHumansNetilmicinEar DiseasesAmikacinAgedAntibacterial agentPharmacologybusiness.industryHealth PolicyOdds ratioMiddle Agedmedicine.diseaseConfidence intervalAnti-Bacterial AgentsSurgeryClinical trialMeta-analysisKidney DiseasesControlled Clinical Trials as TopicGentamicinsbusinessAmerican Journal of Health-System Pharmacy
researchProduct

How should we manage atherogenic dyslipidemia in women with polycystic ovary syndrome?

2007

Despite their young age, women with polycystic ovary syndrome (PCOS) have increased cardiovascular risk. Besides normal concentrations of low-density lipoprotein (LDL) cholesterol, dyslipidemia is very common and includes elevated triglyceride levels and low high-density lipoprotein cholesterol concentrations. Recent findings also showed that women with PCOS have qualitative LDL alterations, with increased levels of atherogenic small, dense LDL particles. Such lipid abnormalities constitute a common form of dyslipidemia, the so-called atherogenic lipoprotein phenotype (ALP), associated with a greater cardiovascular risk. Weight reduction and increased physical activity may constitute first-…

Adultmedicine.medical_specialtySettore MED/09 - Medicina Interna10265 Clinic for Endocrinology and Diabetology610 Medicine & healthRisk AssessmentSeverity of Illness IndexSettore MED/13 - Endocrinologiachemistry.chemical_compoundWeight lossInternal medicinemedicineHumansatherosclerosis high-density lipoprotein cholesterol polycystic ovary syndrome small and dense low-density lipoprotein triglyceridesDyslipidemiasTriglyceridebusiness.industryCholesterolCholesterol HDLnutritional and metabolic diseasesObstetrics and Gynecology2729 Obstetrics and GynecologyCholesterol LDLmedicine.diseaseAtherosclerosisPrognosisPolycystic ovaryMetforminEndocrinologyTreatment OutcomechemistryCardiovascular Diseaseslipids (amino acids peptides and proteins)Drug Therapy CombinationFemaleControlled Clinical Trials as Topicmedicine.symptomHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessPioglitazoneDyslipidemiamedicine.drugLipoproteinPolycystic Ovary Syndrome
researchProduct

Low-molecular-weight heparin to prevent recurrent venous thromboembolism in pregnancy: Rationale and design of the Highlow study, a randomised trial …

2016

Summary Background Women with a history of venous thromboembolism (VTE) have a 2% to 10% absolute risk of VTE recurrence during subsequent pregnancies. Therefore, current guidelines recommend that all pregnant women with a history of VTE receive pharmacologic thromboprophylaxis. The optimal dose of low-molecular-weight heparin (LMWH) for thromboprophylaxis is unknown. In the Highlow study (NCT 01828697; www.highlowstudy.org ), we compare a fixed low dose of LMWH with an intermediate dose of LMWH for the prevention of pregnancy-associated recurrent VTE. We present the rationale and design features of this study. Methods The Highlow study is an investigator-initiated, multicentre, internation…

Adultmedicine.medical_specialtymedicine.drug_classPregnancy Complications CardiovascularLow molecular weight heparinHemorrhage030204 cardiovascular system & hematologylaw.inventionYoung Adult03 medical and health sciencesClinical trials0302 clinical medicineRandomized controlled trialRecurrencePregnancylawInternal medicineVenous thrombosisSecondary PreventionHumansMedicinecardiovascular diseasesPregnancy030219 obstetrics & reproductive medicineProphylaxisbusiness.industryPostpartum PeriodAbsolute risk reductionAnticoagulantsVenous ThromboembolismHematologyHeparinHeparin Low-Molecular-Weightmedicine.diseaseequipment and suppliesLMWHSurgeryClinical trialVenous thrombosisTreatment OutcomeGestationFemalebusinessmedicine.drug
researchProduct

Efficacy and safety of allergen immunotherapy in patients with allergy to molds: A systematic review

2018

BACKGROUND Allergen immunotherapy (AIT) with mould extracts has been performed for many years but the final demonstration of its clinical efficacy is still missing, due to the small number of studies and their inconsistent results. OBJECTIVE To systematically review efficacy and safety of AIT for the treatment of respiratory allergies to moulds. DESIGN The primary outcomes were safety and reduction of symptoms (Symptom Score, SS) and medication use (Medication Score, MS) in patients treated with AIT compared to controls. The strength of the evidence was graded based on the risk of bias, consistency and magnitude of effect, according to the GRADE Working Group's guide. DATA SOURCES Medline, …

Allergen immunotherapymedicine.medical_specialtyAllergyAntigens FungalImmunologyMEDLINECochrane LibraryPlacebo03 medical and health sciences0302 clinical medicinePharmacotherapyInternal medicineHypersensitivityHumansImmunology and AllergyMedicineAnti-Asthmatic Agents030212 general & internal medicineAsthmaClinical Trials as Topicbusiness.industryFungiAllergensmedicine.diseasePhenotypeTreatment Outcome030228 respiratory systemDesensitization ImmunologicSample size determinationbusinessClinical & Experimental Allergy
researchProduct